Research
Hormonal
Liraglutide reduced global eating disorder risk scores.
Practitioners may consider liraglutide as a treatment option for reducing eating disorder risk in patients with obesity or Type 2 diabetes.
StrongSupportsmedium confidence
Liraglutide reduced global eating disorder risk scores, with no differences between groups (k = 1).
Why this rating
Based on the inclusion of multiple studies and the synthesis of data.
Source
GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
Hiba Jebeile et al. · Obesity Reviews · 2025
review · n=8997Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →